Fort Lee, NJ—January 30, 2012 Kedrion Biopharma, Inc. announced today the appointment of Neal Fitzpatrick to the position of Vice President of Sales and Marketing. He comes to Kedrion Biopharma with 29 years of industry experience, including over 14 years in bleeding disorders and 16 years within the specialty pharmacy market.
Fitzpatrick has held a variety of senior management positions, most recently as the National Director of Sales and Marketing at the United Therapeutics Corporation. He will oversee all commercial responsibilities for KBI, including sales, marketing, and customer service.
“Neal Fitzpatrick will bring a wide range of experience and expertise to Kedrion Biopharma, and we are extremely pleased that he is joining the USA team,” states Paolo Marcucci, CEO of Kedrion. “He is a proven leader in building successful sales and marketing teams and launching new products.”
Fitzpatrick’s strategic leadership was critical in helping United Therapeutics become a key player in the Pulmonary Arterial Hypertension (PAH) orphan disease space. Additionally, he has achieved great success in building teams and driving sales as the Associate Vice President of Biopharma Sales at Novo Nordisk, Inc., the Senior Group Marketing Director of Hematology and Oncology at Pfizer, Inc., and Vice President of Global Marketing at Skye Pharma LLC.
About Kedrion Biopharma
Kedrion Biopharma Inc. United States is a fully owned subsidiary of Kedrion S.p.A, headquartered in Italy. Kedrion develops, manufactures and distributes human plasma derived products, which improve people’s quality of life. The company plays a major role worldwide providing critical therapies in 40 other countries. The company’s focus is on providing high quality products, relentless pursuit of research and development, and on the building of substantial industrial capacity to ensure continuous supply.
Additional information about Kedrion can be found at www.kedrionusa.com.
